Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-102591
Filing Date
2025-10-27
Accepted
2025-10-27 16:05:30
Documents
4

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 10566
2 EXHIBIT 1 tm2529373d1_ex1.htm EX-24.1 6235
3 EXHIBIT 2 tm2529373d1_ex2.htm EX-24.2 6196
4 EXHIBIT 3 tm2529373d1_ex3.htm EX-99.1 5594
  Complete submission text file 0001104659-25-102591.txt   30375
Mailing Address TWO MANHATTAN WEST 375 NINTH AVENUE, 52ND FLOOR NEW YORK NY 10001
Business Address TWO MANHATTAN WEST 375 NINTH AVENUE, 52ND FLOOR NEW YORK NY 10001 212-478-0000
D. E. SHAW & CO, L.P. (Filed by) CIK: 0001009268 (see all company filings)

EIN.: 133695715 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91484 | Film No.: 251419903
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)